Latest news with #SigachiIndustries
Business Standard
2 days ago
- Business
- Business Standard
Sigachi Industries consolidated net profit declines 11.77% in the March 2025 quarter
Sales rise 23.12% to Rs 128.20 crore Net profit of Sigachi Industries declined 11.77% to Rs 13.27 crore in the quarter ended March 2025 as against Rs 15.04 crore during the previous quarter ended March 2024. Sales rose 23.12% to Rs 128.20 crore in the quarter ended March 2025 as against Rs 104.13 crore during the previous quarter ended March 2024. For the full year,net profit rose 21.65% to Rs 69.56 crore in the year ended March 2025 as against Rs 57.18 crore during the previous year ended March 2024. Sales rose 22.38% to Rs 488.24 crore in the year ended March 2025 as against Rs 398.96 crore during the previous year ended March 2024. Particulars Quarter Ended Year Ended Mar. 2025 Mar. 2024 % Var. Mar. 2025 Mar. 2024 % Var. Sales 128.20104.13 23 488.24398.96 22 OPM % 22.2815.69 - 20.4819.21 - PBDT 27.4120.70 32 108.0980.57 34 PBT 22.6717.21 32 92.3269.77 32 NP 13.2715.04 -12 69.5657.18 22
Hans India
3 days ago
- Business
- Hans India
Sigachi Industries reports 21 pc drop in net profit in Q4, revenue also declines
Sigachi Industries Limited has announced that the company's net profit fell by approximately 21.16 per cent, coming down to Rs 16.17 crore in Q4 from Rs 20.51 crore in the previous quarter. This dip comes alongside a decline in both revenue from operations and total income. Revenue from operations in Q4 stood at Rs 128.2 crore, down from Rs 139.41 crore in the previous quarter -- a fall of about 8.04 per cent. Total income also dropped to Rs 130.39 crore in Q4 compared to Rs 141.43 crore in Q3, marking a 7.81 per cent decrease. Despite the quarter-on-quarter (QoQ) decline, the company remains optimistic about its growth prospects. Commenting on the performance and outlook, Sigachi Industries Managing Director and CEO Amit Raj Sinha said: "FY25 has been a transformative year for Sigachi, marked by robust financial outcomes and strategic expansions across excipients and APIs." "With our Hyderabad API R&D centre going live in Q1 FY26, regulatory approvals flowing in, and global market penetration deepening, we are positioned for sustainable high-margin growth," he said. "Our 36-year legacy and diversified portfolio give us an unmatched advantage to scale operations globally while safeguarding profitability," he added. "The company is expanding its footprint beyond India, the US, and Europe by aggressively entering Latin America, Southeast Asia, and the Middle East through new distribution partnerships and turnkey O&M contracts," Sigachi said in its filing. Sigachi Industries, founded in 1989 and headquartered in Hyderabad, is a manufacturer in the field of pharma excipients, nutraceuticals, and food ingredients. The company is known for its global leadership in the production of microcrystalline cellulose (MCC), with manufacturing facilities in India and subsidiaries operating internationally. The company serves a broad spectrum of industries, including pharmaceuticals, food and beverages, nutraceuticals, and cosmetics.
Business Standard
07-05-2025
- Business
- Business Standard
Trimax Biosciences achieves EDQM Certificate of Suitability for Metformin Hydrochloride
Sigachi Industries announced that Trimax Biosciences, a Sigachi Group Company has successfully achieved the Certificate of Suitability (CEP) for Metformin Hydrochloride from European Directorate for the Quality of Medicines & Health Care (EDQM). This milestone paves the way for Trimax to export this crucial Active Pharmaceutical Ingredient (API) to Europe and other CEP-accepting markets, further strengthening Sigachi's presence in highly regulated pharmaceutical markets. Powered by Capital Market - Live News
Mint
28-04-2025
- Business
- Mint
Pharma stock jumps 5% from today's low after this MoU update. Do you own?
Pharmaceuticals sector stock Sigachi Industries bounced back 5 per cent from its intraday low after a wholly owned subsidiary of the company, on Monday, April 28, signed a memorandum of understanding (Mou) with Respilon Group to work on nanofiber-based drug delivery technologies, according to an exchange filing. 'Sigachi Industries Limited, a leading player in pharmaceutical industry is pleased to announce that its wholly owned subsidiary, Sigachi MENA FZCO, has signed a Memorandum of Understanding (MoU) with Respilon Group s.r.o to advance nanofiber-based drug delivery technologies,' said the company in the BSE filing. According to the filing data, the company aims to leverage Respilon's patented nanofiber technology to transform the patient experience and therapeutic outcomes as the firm seeks to deliver a non-invasive, precision drug delivery system. 'Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX® technology offers to revolutionize drug delivery systems globally,' said Amit Raj Sinha, the managing director and chief executive officer of Sigachi Industries. The strategic collaboration also includes developing commercialisation strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology, according to the exchange filing. Sigachi Industries shares hit an intraday high of ₹ 43.93 after the company announced the MoU update on Monday. The shares gained an overall 5.09 per cent to hit those highs from today's low of ₹ 41.80 per share. The shares closed 1.10% higher at ₹ 43.29 after the stock market session on Monday, April 28, compared to ₹ 42.82 at the previous stock market close, according to the BSE data. Sigachi Industries shares have given stock market investors 22.91 per cent returns in the last one-month period, and the stock is currently trading above its year-low levels, which it hit in February 2025. The shares hit their 52-week high level at ₹ 75.45 on May 27, 2025, while the 52-week low level was at ₹ 34.51 on February 17, 2025, according to the data collected from the BSE website.
Business Standard
28-04-2025
- Business
- Business Standard
Sigachi Industries inks MoU with Czech Republic-based Respilon Group
Sigachi Industries said that its wholly owned subsidiary Sigachi MENA FZCO has signed a memorandum of understanding (MoU) with Respilon to expand into advanced drug delivery technologies. Headquartered in the Czech Republic, Respilon is an innovation-driven nanofiber R&D company. Sigachi and Respilon will collaborate to develop, manufacture, and commercialize drug delivery solutions based on Respilons proprietary NUENEX nanofiber technology. The two entities would focus on the development of Invisible Patch and Powder-based pharmaceutical delivery formats. The collaboration includes developing commercialization strategies for relevant APIs and formulations, leveraging nanofiber encapsulation technology. Amit Raj Sinha, managing director and CEO of Sigachi Industries, said: "Partnering with Respilon aligns perfectly with our vision to deliver next-generation pharmaceutical solutions that improve therapeutic outcomes and elevate the patient experience. We are excited about the possibilities NUENEX technology offers to revolutionize drug delivery systems globally. Telangana-based Sigachi Industries is engaged in the manufacturing of microcrystalline cellulose (MCC), which is widely used in the pharmaceutical, food, beverage, cosmetic, and paint industries. The most common uses of MCC are in vitamin supplements and tablets. It also acts as a bulking agent in food production. MCC is produced from refined wood pulp, which is imported by the company. The company reported 32.52% jump in consolidated net profit to Rs 21.35 crore in Q3 FY25 from Rs 16.11 crore posted in Q3 FY24. Revenue from operations grew by 25.66% to Rs 139.41 crore in Q3 FY25 from Rs 110.94 crore registered in Q3 FY24. The scrip rose 0.30% to currently trade at Rs 42.95 on the BSE.
